Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381888 · ClinicalTrials.gov registry record · Phase 2
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00381888 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 44 participants.
The verdict
NCT00381888, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer. PURPOSE: This phase II trial is studying how well fondaparinux works in preventing blood clots in patients undergoing surgery for gynecologic cancer.
Interventions
- DRUG fondaparinux sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381888
The ClinicalTrials.gov registry entry for NCT00381888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fondaparinux sodium is the first listed.
NCT00381888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381888 about?
NCT00381888 is a clinical study titled "Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer". RATIONALE: Fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer. PURPOSE: This phase II trial is studying how well fondaparinux works in preventing blood clots in patients undergoing surgery for gynecologic cancer.
What is the current status of trial NCT00381888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2007-01. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00381888?
The interventions under investigation include: fondaparinux sodium (DRUG).
Who is sponsoring clinical trial NCT00381888?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.